Solventum Corp. 8-K: Effectiveness of Registration Statement

Ticker: SOLV · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1964738

Solventum Corp 8-K Filing Summary
FieldDetail
CompanySolventum Corp (SOLV)
Form Type8-K
Filed DateMar 13, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: spin-off, corporate-action, procedural

Related Tickers: MMM

TL;DR

Solventum's registration statement is effective, paving the way for its spin-off from 3M.

AI Summary

Solventum Corporation, formerly 3M Health Care Co., filed an 8-K on March 13, 2024, to report the effectiveness of its previously filed registration statement. This filing is a procedural step related to its separation from 3M Company, with its principal executive offices located at 3M Center, St. Paul, MN.

Why It Matters

This filing marks a key procedural milestone for Solventum's separation from 3M, signaling progress towards its independent operation as a public company.

Risk Assessment

Risk Level: low — This is a routine procedural filing related to a corporate separation and does not introduce new financial or operational risks.

Key Numbers

  • 001-41968 — SEC File Number (Identifies the company's filing with the SEC.)
  • 92-2008841 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • Solventum Corporation (company) — Registrant
  • 3M Company (company) — Former Parent Company
  • 3M Health Care Co. (company) — Former Name
  • March 13, 2024 (date) — Filing Date
  • Delaware (jurisdiction) — State of Incorporation
  • 3M Center, Building 275-6W (address) — Principal Executive Offices
  • St. Paul, MN (location) — City and State of Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing for Solventum Corporation?

The primary purpose is to report the effectiveness of its previously filed registration statement, a procedural step related to its separation from 3M Company.

When was this 8-K filing made?

The filing was made on March 13, 2024.

What was Solventum Corporation's former name?

Solventum Corporation's former name was 3M Health Care Co.

Where are Solventum Corporation's principal executive offices located?

Solventum Corporation's principal executive offices are located at 3M Center, Building 275-6W, St. Paul, MN 55144-1000.

What is the SEC file number for Solventum Corporation?

The SEC file number for Solventum Corporation is 001-41968.

Filing Stats: 945 words · 4 min read · ~3 pages · Grade level 12.1 · Accepted 2024-03-13 17:12:37

Key Financial Figures

  • $0.01 — ich registered Common Stock, par value $0.01 per share SOLV New York Stock Exchange

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Information Statement Solventum Corporation ("Solventum"), a wholly owned subsidiary of 3M Company ("3M"), previously filed with the U.S. Securities and Exchange Commission a registration statement on Form 10 (as amended, the "Registration Statement") relating to the planned distribution by 3M of 80.1% of the issued and outstanding shares of common stock, par value $0.01 per share, of Solventum (the "Solventum common stock") to 3M shareholders. On March 13, 2024, the Registration Statement was declared effective. The Registration Statement includes a preliminary information statement that describes the planned distribution and includes other important information regarding Solventum, including about its business and management. The final information statement, dated March 13, 2024 (the "Information Statement"), is attached hereto as Exhibit 99.1. As further described in the Information Statement, 3M expects to distribute one share of Solventum common stock for every four shares of 3M common stock held as of the close of business on March 18, 2024, the record date for the distribution, with cash paid in lieu of fractional shares of Solventum common stock. Subject to the satisfaction or waiver of the conditions to the distribution, which are described in the Information Statement, the distribution is expected to occur prior to the opening of trading on April 1, 2024. Beginning on or about March 26, 2024, Solventum common stock is expected to begin trading on a "when-issued" basis on the New York Stock Exchange (the "NYSE") under the symbol "SOLV WI," with such trading on a "when-issued" basis ending at the close of trading on March 28, 2024. Beginning on April 1, 2024, Solventum common stock is expected to begin regular way trading on the NYSE under the ticker "SOLV." Investor Day Solventum will host an investor day in New York City on Tuesday, March 19, 2024 at 900 a.m. Eastern Time in connection with the planned spin-off of

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following is furnished as an exhibit to this report Exhibit No. Description 99.1 Information Statement of Solventum Corporation, dated March 13 , 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLVENTUM CORPORATION By s Teresa Crockett Name Teresa Crockett Title President Date March 13, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.